Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Resorbable Coronary Magnesium Scaffold System (Freesolve®) in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries: BIOMAG-II: A Randomized Controlled Trial

NCT05540223 is registered in ClinicalTrials.gov with Biotronik AG as lead sponsor.

NCT NCT05540223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05540223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Resorbable Coronary Magnesium Scaffold System (Freesolve®) in the Treatment of Subjects With de Novo Lesions in Native Coronary Arteries: BIOMAG-II: A Randomized Controlled Trial
Lead sponsor
Biotronik AG
Phase
Not applicable
Overall status
Active, not recruiting
Start date
May 13, 2024
Completion date
February 29, 2032
Enrollment
1,861 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome, angina pectoris, atherosclerosis, coronary, coronary artery disease, ischemic heart disease, myocardial ischemia